Prevalence of Immunosuppressive Drug Use Among Commercially Insured US Adults, 2018-2019

Beth I Wallace; Brooke Kenney; Preeti N Malani; Daniel J Clauw; Brahmajee K Nallamothu; Akbar K Waljee

doi:10.1001/jamanetworkopen.2021.4920

Prevalence of Immunosuppressive Drug Use Among Commercially Insured US Adults, 2018-2019

JAMA Netw Open. 2021 May 3;4(5):e214920. doi: 10.1001/jamanetworkopen.2021.4920.

Authors

Beth I Wallace^{1

2}, Brooke Kenney³, Preeti N Malani¹, Daniel J Clauw⁴, Brahmajee K Nallamothu¹, Akbar K Waljee^{1

2}

Affiliations

¹ Department of Internal Medicine, University of Michigan Medical School, Ann Arbor.
² VA Center for Clinical Management Research, VA Ann Arbor Healthcare System, Ann Arbor, Michigan.
³ Department of Surgery, University of Michigan Medical School, Ann Arbor.
⁴ Department of Anesthesiology, University of Michigan Medical School, Ann Arbor.

Abstract

This cross-sectional study uses direct pharmaceutical claims data from a commercial claims database to assess the use of 6 types of immunosuppressive drugs among commercially insured US adults in 2018 and 2019.

Publication types

Research Support, N.I.H., Extramural

MeSH terms

Adult
Cross-Sectional Studies
Female
Humans
Immunocompromised Host*
Immunosuppressive Agents / adverse effects*
Immunosuppressive Agents / therapeutic use*
Infections / etiology
Insurance, Health*
Male
Methotrexate / adverse effects
Methotrexate / therapeutic use
Methylprednisolone / adverse effects
Methylprednisolone / therapeutic use
Middle Aged
Prednisone / adverse effects
Prednisone / therapeutic use
Risk Factors
United States
Young Adult

Substances

Immunosuppressive Agents
Prednisone
Methylprednisolone
Methotrexate